| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Obesity | 106 | 2019 | 1866 | 8.840 |
Why?
|
| Hypertension | 71 | 2022 | 842 | 7.440 |
Why?
|
| Blood Pressure | 77 | 2022 | 1234 | 5.650 |
Why?
|
| Cardiovascular Diseases | 80 | 2022 | 1211 | 5.440 |
Why?
|
| Body Mass Index | 87 | 2021 | 1434 | 5.210 |
Why?
|
| Attitude | 188 | 2018 | 47516 | 4.840 |
Why?
|
| Social Responsibility | 187 | 2018 | 47385 | 4.840 |
Why?
|
| Students | 188 | 2018 | 47688 | 4.830 |
Why?
|
| Engineering | 186 | 2018 | 47370 | 4.830 |
Why?
|
| Child | 266 | 2022 | 12453 | 4.350 |
Why?
|
| Adolescent | 457 | 2022 | 60563 | 3.900 |
Why?
|
| Hyperlipoproteinemia Type II | 10 | 2021 | 18 | 3.750 |
Why?
|
| Humans | 613 | 2022 | 128242 | 3.700 |
Why?
|
| Pediatric Obesity | 13 | 2019 | 281 | 3.390 |
Why?
|
| Obesity, Morbid | 15 | 2017 | 124 | 3.280 |
Why?
|
| Female | 461 | 2022 | 92196 | 3.220 |
Why?
|
| Male | 405 | 2022 | 90667 | 2.960 |
Why?
|
| Metabolic Syndrome | 21 | 2015 | 303 | 2.900 |
Why?
|
| Adult | 333 | 2022 | 70001 | 2.850 |
Why?
|
| Longitudinal Studies | 225 | 2020 | 49312 | 2.640 |
Why?
|
| Young Adult | 238 | 2022 | 55149 | 2.590 |
Why?
|
| Dyslipidemias | 16 | 2019 | 113 | 2.570 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 15 | 2021 | 53 | 2.450 |
Why?
|
| Surveys and Questionnaires | 201 | 2018 | 50539 | 2.440 |
Why?
|
| Interviews as Topic | 187 | 2018 | 47819 | 2.400 |
Why?
|
| Socialization | 186 | 2018 | 47368 | 2.400 |
Why?
|
| Curriculum | 188 | 2018 | 47915 | 2.380 |
Why?
|
| Pediatrics | 21 | 2022 | 729 | 2.220 |
Why?
|
| Mass Screening | 15 | 2019 | 778 | 2.120 |
Why?
|
| Cholesterol, LDL | 19 | 2019 | 216 | 2.080 |
Why?
|
| Risk Factors | 99 | 2022 | 6441 | 2.060 |
Why?
|
| Adiposity | 12 | 2020 | 346 | 2.030 |
Why?
|
| Hypertrophy, Left Ventricular | 22 | 2021 | 79 | 2.010 |
Why?
|
| Blood Pressure Determination | 13 | 2020 | 90 | 2.000 |
Why?
|
| Atherosclerosis | 14 | 2015 | 212 | 1.940 |
Why?
|
| Diet | 19 | 2015 | 767 | 1.930 |
Why?
|
| Diabetes Mellitus, Type 2 | 30 | 2022 | 1416 | 1.810 |
Why?
|
| Adipose Tissue | 13 | 2011 | 466 | 1.760 |
Why?
|
| Child, Preschool | 93 | 2022 | 6811 | 1.660 |
Why?
|
| Pain, Postoperative | 8 | 2013 | 137 | 1.660 |
Why?
|
| Primary Prevention | 6 | 2015 | 158 | 1.650 |
Why?
|
| Vascular Stiffness | 12 | 2019 | 271 | 1.620 |
Why?
|
| Insulin Resistance | 15 | 2022 | 785 | 1.570 |
Why?
|
| Hypercholesterolemia | 11 | 2017 | 63 | 1.560 |
Why?
|
| Prevalence | 45 | 2021 | 1722 | 1.540 |
Why?
|
| Lipids | 21 | 2018 | 459 | 1.500 |
Why?
|
| Exercise | 20 | 2019 | 1173 | 1.430 |
Why?
|
| Weight Loss | 15 | 2018 | 500 | 1.420 |
Why?
|
| Life Style | 16 | 2019 | 321 | 1.420 |
Why?
|
| Diclofenac | 6 | 2013 | 10 | 1.390 |
Why?
|
| Antihypertensive Agents | 11 | 2018 | 315 | 1.370 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 8 | 2013 | 229 | 1.370 |
Why?
|
| Practice Guidelines as Topic | 21 | 2021 | 1104 | 1.340 |
Why?
|
| Feeding Behavior | 13 | 2020 | 386 | 1.340 |
Why?
|
| Body Constitution | 13 | 2007 | 46 | 1.330 |
Why?
|
| Carotid Arteries | 9 | 2013 | 125 | 1.320 |
Why?
|
| Energy Intake | 17 | 2020 | 328 | 1.310 |
Why?
|
| Diet, Reducing | 9 | 2017 | 65 | 1.290 |
Why?
|
| Heart Rate | 16 | 2019 | 584 | 1.240 |
Why?
|
| Heart Defects, Congenital | 9 | 2019 | 522 | 1.220 |
Why?
|
| Age Factors | 44 | 2015 | 2277 | 1.210 |
Why?
|
| United States | 77 | 2021 | 8885 | 1.200 |
Why?
|
| Hyperlipidemias | 4 | 2012 | 102 | 1.190 |
Why?
|
| Diabetes Mellitus, Type 1 | 25 | 2022 | 2293 | 1.190 |
Why?
|
| Bariatric Surgery | 9 | 2017 | 116 | 1.120 |
Why?
|
| Gastric Bypass | 7 | 2017 | 67 | 1.090 |
Why?
|
| Echocardiography | 35 | 2021 | 471 | 1.080 |
Why?
|
| American Heart Association | 19 | 2019 | 202 | 1.070 |
Why?
|
| Prehypertension | 3 | 2012 | 16 | 1.070 |
Why?
|
| Cardiovascular Agents | 2 | 2014 | 83 | 1.060 |
Why?
|
| Cardiovascular System | 5 | 2021 | 75 | 1.030 |
Why?
|
| Overweight | 10 | 2019 | 341 | 1.020 |
Why?
|
| Regression Analysis | 25 | 2014 | 813 | 0.970 |
Why?
|
| Risk Assessment | 18 | 2019 | 2143 | 0.970 |
Why?
|
| Arteriosclerosis | 10 | 2013 | 85 | 0.960 |
Why?
|
| Cholesterol, HDL | 12 | 2015 | 183 | 0.950 |
Why?
|
| Bulimia Nervosa | 3 | 2007 | 18 | 0.950 |
Why?
|
| African Americans | 16 | 2016 | 797 | 0.940 |
Why?
|
| Mucocutaneous Lymph Node Syndrome | 6 | 2018 | 75 | 0.940 |
Why?
|
| Hypolipidemic Agents | 4 | 2012 | 66 | 0.930 |
Why?
|
| Body Weight | 15 | 2019 | 731 | 0.930 |
Why?
|
| Dietary Carbohydrates | 8 | 2015 | 113 | 0.920 |
Why?
|
| Ohio | 21 | 2016 | 96 | 0.910 |
Why?
|
| Ventricular Dysfunction, Left | 9 | 2020 | 274 | 0.910 |
Why?
|
| Kidney Failure, Chronic | 7 | 2008 | 282 | 0.890 |
Why?
|
| Body Composition | 12 | 2011 | 531 | 0.880 |
Why?
|
| Anticholesteremic Agents | 4 | 2020 | 97 | 0.860 |
Why?
|
| Diabetes Complications | 6 | 2015 | 172 | 0.860 |
Why?
|
| Maternal Health | 1 | 2021 | 31 | 0.860 |
Why?
|
| Double-Blind Method | 17 | 2020 | 1191 | 0.850 |
Why?
|
| Coronary Aneurysm | 3 | 2018 | 10 | 0.850 |
Why?
|
| Pulse Wave Analysis | 7 | 2022 | 120 | 0.840 |
Why?
|
| Waist Circumference | 13 | 2015 | 104 | 0.840 |
Why?
|
| Treatment Outcome | 23 | 2020 | 6403 | 0.830 |
Why?
|
| Carotid Intima-Media Thickness | 3 | 2018 | 45 | 0.830 |
Why?
|
| Ventricular Function, Left | 14 | 2003 | 331 | 0.820 |
Why?
|
| Laparoscopy | 2 | 2017 | 290 | 0.810 |
Why?
|
| Systole | 10 | 2010 | 118 | 0.800 |
Why?
|
| Prospective Studies | 29 | 2022 | 4425 | 0.800 |
Why?
|
| Infant | 50 | 2022 | 5727 | 0.790 |
Why?
|
| Heterozygote | 1 | 2020 | 206 | 0.790 |
Why?
|
| Oil and Gas Fields | 1 | 2019 | 23 | 0.780 |
Why?
|
| Risk Reduction Behavior | 10 | 2014 | 161 | 0.770 |
Why?
|
| Maternal Exposure | 3 | 2019 | 105 | 0.760 |
Why?
|
| Diastole | 13 | 2020 | 105 | 0.760 |
Why?
|
| Nervous System Malformations | 1 | 2018 | 20 | 0.750 |
Why?
|
| Phenols | 2 | 2009 | 54 | 0.740 |
Why?
|
| Decision Making | 2 | 2014 | 558 | 0.740 |
Why?
|
| Circadian Rhythm | 5 | 2014 | 342 | 0.740 |
Why?
|
| Absorptiometry, Photon | 12 | 2010 | 167 | 0.740 |
Why?
|
| Depressive Disorder, Major | 2 | 2019 | 229 | 0.740 |
Why?
|
| Morbidity | 4 | 2017 | 185 | 0.730 |
Why?
|
| Walk Test | 1 | 2018 | 47 | 0.730 |
Why?
|
| Cohort Studies | 30 | 2015 | 3676 | 0.720 |
Why?
|
| Deafness | 1 | 2018 | 40 | 0.720 |
Why?
|
| Blood Glucose | 16 | 2022 | 1365 | 0.720 |
Why?
|
| Infant, Newborn | 29 | 2019 | 3619 | 0.710 |
Why?
|
| Tooth Extraction | 5 | 2016 | 15 | 0.710 |
Why?
|
| Follow-Up Studies | 27 | 2020 | 3446 | 0.710 |
Why?
|
| Internationality | 2 | 2015 | 110 | 0.700 |
Why?
|
| Biomarkers | 6 | 2019 | 2583 | 0.690 |
Why?
|
| Diabetic Angiopathies | 7 | 2019 | 222 | 0.690 |
Why?
|
| Anti-Obesity Agents | 5 | 2018 | 23 | 0.690 |
Why?
|
| Sex Factors | 20 | 2017 | 1441 | 0.680 |
Why?
|
| Air Pollution | 1 | 2019 | 145 | 0.680 |
Why?
|
| Sleep Apnea Syndromes | 3 | 2007 | 61 | 0.680 |
Why?
|
| Health Status | 5 | 2016 | 557 | 0.670 |
Why?
|
| Hearing Loss | 1 | 2018 | 91 | 0.660 |
Why?
|
| Depression | 6 | 2006 | 825 | 0.660 |
Why?
|
| Diet Records | 11 | 2020 | 61 | 0.650 |
Why?
|
| Diet, Carbohydrate-Restricted | 2 | 2017 | 23 | 0.650 |
Why?
|
| Heart | 9 | 2005 | 509 | 0.640 |
Why?
|
| Intra-Abdominal Fat | 2 | 2015 | 62 | 0.640 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2020 | 447 | 0.640 |
Why?
|
| Nanotechnology | 3 | 2016 | 97 | 0.640 |
Why?
|
| Adolescent Development | 3 | 2012 | 81 | 0.640 |
Why?
|
| Graphite | 1 | 2016 | 9 | 0.630 |
Why?
|
| Ketorolac | 2 | 2013 | 15 | 0.630 |
Why?
|
| Triglycerides | 16 | 2016 | 397 | 0.620 |
Why?
|
| Self Disclosure | 2 | 2006 | 48 | 0.620 |
Why?
|
| Central Nervous System Stimulants | 2 | 2009 | 104 | 0.610 |
Why?
|
| Brachial Artery | 4 | 2013 | 135 | 0.610 |
Why?
|
| Body Image | 3 | 2004 | 46 | 0.610 |
Why?
|
| Feeding and Eating Disorders | 5 | 2004 | 76 | 0.610 |
Why?
|
| Carbonated Beverages | 2 | 2006 | 18 | 0.590 |
Why?
|
| Heart Ventricles | 16 | 2010 | 531 | 0.590 |
Why?
|
| Physician's Role | 3 | 2016 | 140 | 0.590 |
Why?
|
| Population Surveillance | 3 | 2019 | 325 | 0.590 |
Why?
|
| Walking | 1 | 2018 | 279 | 0.580 |
Why?
|
| Wind | 1 | 2014 | 10 | 0.580 |
Why?
|
| Ventricular Remodeling | 4 | 2020 | 150 | 0.580 |
Why?
|
| Nanostructures | 1 | 2016 | 77 | 0.580 |
Why?
|
| Vegetables | 6 | 2020 | 87 | 0.580 |
Why?
|
| Caffeine | 2 | 2006 | 52 | 0.580 |
Why?
|
| Emigrants and Immigrants | 1 | 2016 | 71 | 0.580 |
Why?
|
| Hallux Valgus | 4 | 2016 | 24 | 0.580 |
Why?
|
| Reference Values | 21 | 2017 | 575 | 0.580 |
Why?
|
| Cross-Sectional Studies | 27 | 2021 | 3117 | 0.570 |
Why?
|
| Physical Fitness | 4 | 2010 | 114 | 0.570 |
Why?
|
| Orthopedic Procedures | 3 | 2016 | 147 | 0.570 |
Why?
|
| Public Health | 6 | 2014 | 310 | 0.570 |
Why?
|
| Rain | 1 | 2014 | 27 | 0.570 |
Why?
|
| Diabetes Mellitus | 4 | 2016 | 636 | 0.560 |
Why?
|
| Gastroplasty | 2 | 2004 | 12 | 0.560 |
Why?
|
| Cardiopulmonary Resuscitation | 1 | 2017 | 163 | 0.560 |
Why?
|
| Schools | 3 | 2017 | 282 | 0.560 |
Why?
|
| Middle Aged | 50 | 2020 | 20385 | 0.560 |
Why?
|
| Naproxen | 3 | 2016 | 11 | 0.550 |
Why?
|
| Regional Blood Flow | 2 | 2015 | 347 | 0.540 |
Why?
|
| Child Welfare | 6 | 2012 | 143 | 0.540 |
Why?
|
| Exercise Test | 8 | 2018 | 436 | 0.540 |
Why?
|
| Ibuprofen | 2 | 2016 | 47 | 0.540 |
Why?
|
| Patient Compliance | 6 | 2014 | 438 | 0.530 |
Why?
|
| Sleep Apnea, Obstructive | 5 | 2020 | 157 | 0.530 |
Why?
|
| Health Promotion | 8 | 2016 | 454 | 0.520 |
Why?
|
| Cholesterol | 10 | 2022 | 264 | 0.510 |
Why?
|
| Predictive Value of Tests | 10 | 2017 | 1454 | 0.510 |
Why?
|
| Growth Charts | 1 | 2012 | 5 | 0.510 |
Why?
|
| Incidence | 13 | 2020 | 1791 | 0.490 |
Why?
|
| Faculty, Medical | 3 | 2012 | 143 | 0.490 |
Why?
|
| Breast Feeding | 3 | 2016 | 258 | 0.490 |
Why?
|
| Time Factors | 24 | 2017 | 5005 | 0.490 |
Why?
|
| Fruit | 5 | 2020 | 87 | 0.490 |
Why?
|
| Temperature | 1 | 2014 | 471 | 0.480 |
Why?
|
| Fasting | 6 | 2020 | 189 | 0.480 |
Why?
|
| Disease Management | 3 | 2012 | 436 | 0.480 |
Why?
|
| Coronary Disease | 7 | 2011 | 327 | 0.470 |
Why?
|
| Beverages | 2 | 2009 | 48 | 0.460 |
Why?
|
| Career Mobility | 1 | 2012 | 47 | 0.460 |
Why?
|
| Mothers | 3 | 2012 | 423 | 0.460 |
Why?
|
| Child Development | 3 | 2016 | 342 | 0.450 |
Why?
|
| Ductus Arteriosus, Patent | 2 | 2009 | 33 | 0.450 |
Why?
|
| Adolescent Behavior | 7 | 2014 | 375 | 0.450 |
Why?
|
| Glycated Hemoglobin A | 9 | 2022 | 597 | 0.450 |
Why?
|
| Tunica Media | 5 | 2011 | 24 | 0.450 |
Why?
|
| Case-Control Studies | 10 | 2019 | 2288 | 0.450 |
Why?
|
| Sleep | 6 | 2019 | 507 | 0.450 |
Why?
|
| Age of Onset | 12 | 2013 | 378 | 0.450 |
Why?
|
| Food Preferences | 3 | 2011 | 113 | 0.440 |
Why?
|
| Disease Progression | 8 | 2019 | 1803 | 0.440 |
Why?
|
| Dietary Sucrose | 3 | 2015 | 46 | 0.440 |
Why?
|
| Puberty | 8 | 2018 | 81 | 0.440 |
Why?
|
| Dysmenorrhea | 2 | 2008 | 5 | 0.440 |
Why?
|
| Anthropometry | 9 | 2018 | 138 | 0.430 |
Why?
|
| Logistic Models | 8 | 2019 | 1463 | 0.430 |
Why?
|
| Health Behavior | 8 | 2016 | 543 | 0.430 |
Why?
|
| Academic Medical Centers | 2 | 2016 | 315 | 0.420 |
Why?
|
| Family Health | 5 | 2012 | 152 | 0.420 |
Why?
|
| Diabetes, Gestational | 4 | 2018 | 194 | 0.420 |
Why?
|
| Severity of Illness Index | 13 | 2017 | 1983 | 0.420 |
Why?
|
| Acute Pain | 3 | 2016 | 24 | 0.410 |
Why?
|
| Adiponectin | 3 | 2010 | 165 | 0.410 |
Why?
|
| Pregnancy | 13 | 2021 | 3839 | 0.400 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 2 | 2013 | 14 | 0.400 |
Why?
|
| Methylphenidate | 1 | 2009 | 19 | 0.400 |
Why?
|
| Cardiology | 4 | 2019 | 218 | 0.400 |
Why?
|
| Colorado | 10 | 2019 | 3230 | 0.390 |
Why?
|
| Energy Metabolism | 5 | 2006 | 626 | 0.390 |
Why?
|
| Oxycodone | 1 | 2009 | 27 | 0.390 |
Why?
|
| Bone Density | 2 | 2010 | 276 | 0.390 |
Why?
|
| Dose-Response Relationship, Drug | 7 | 2016 | 1588 | 0.390 |
Why?
|
| Poloxamer | 1 | 2009 | 14 | 0.390 |
Why?
|
| Sweetening Agents | 1 | 2009 | 35 | 0.390 |
Why?
|
| Neurotransmitter Agents | 1 | 2009 | 62 | 0.380 |
Why?
|
| Heart Murmurs | 1 | 2009 | 13 | 0.380 |
Why?
|
| Hypertension, Pulmonary | 2 | 2017 | 1152 | 0.380 |
Why?
|
| Demography | 4 | 2016 | 218 | 0.380 |
Why?
|
| Nutrition Surveys | 4 | 2015 | 152 | 0.370 |
Why?
|
| Multivariate Analysis | 8 | 2021 | 1098 | 0.370 |
Why?
|
| Hemodynamics | 9 | 2003 | 801 | 0.370 |
Why?
|
| Tunica Intima | 5 | 2011 | 58 | 0.370 |
Why?
|
| Vascular Resistance | 5 | 2011 | 271 | 0.370 |
Why?
|
| Hand Strength | 1 | 2009 | 74 | 0.360 |
Why?
|
| Dietary Fats | 8 | 2011 | 256 | 0.360 |
Why?
|
| Aged | 25 | 2016 | 14374 | 0.360 |
Why?
|
| Caloric Restriction | 1 | 2009 | 86 | 0.360 |
Why?
|
| Milk | 1 | 2009 | 104 | 0.360 |
Why?
|
| Metabolic Diseases | 1 | 2009 | 89 | 0.360 |
Why?
|
| Eosinophilia-Myalgia Syndrome | 3 | 1996 | 3 | 0.360 |
Why?
|
| Growth Disorders | 1 | 2008 | 50 | 0.350 |
Why?
|
| Peripheral Arterial Disease | 1 | 2012 | 251 | 0.350 |
Why?
|
| Infant, Small for Gestational Age | 1 | 2008 | 48 | 0.350 |
Why?
|
| Gastrointestinal Tract | 1 | 2009 | 107 | 0.350 |
Why?
|
| Attitude to Health | 3 | 2006 | 278 | 0.350 |
Why?
|
| Growth Hormone | 1 | 2008 | 84 | 0.350 |
Why?
|
| Diet, Fat-Restricted | 4 | 2007 | 68 | 0.350 |
Why?
|
| Cyclobutanes | 1 | 2007 | 2 | 0.350 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 2009 | 88 | 0.350 |
Why?
|
| Counseling | 3 | 2017 | 246 | 0.350 |
Why?
|
| Appetite Depressants | 1 | 2007 | 11 | 0.350 |
Why?
|
| Heart Atria | 3 | 2010 | 87 | 0.340 |
Why?
|
| Birth Weight | 2 | 2009 | 295 | 0.340 |
Why?
|
| Tryptophan | 3 | 1996 | 94 | 0.330 |
Why?
|
| Adenoidectomy | 2 | 2020 | 35 | 0.330 |
Why?
|
| Sleep Wake Disorders | 3 | 2018 | 206 | 0.330 |
Why?
|
| Evidence-Based Medicine | 7 | 2012 | 523 | 0.330 |
Why?
|
| Bulimia | 2 | 2006 | 13 | 0.330 |
Why?
|
| Aortic Coarctation | 4 | 2004 | 43 | 0.330 |
Why?
|
| Research Design | 5 | 2018 | 645 | 0.330 |
Why?
|
| Uric Acid | 1 | 2009 | 224 | 0.330 |
Why?
|
| Cardiac Output | 7 | 2005 | 109 | 0.330 |
Why?
|
| Body Height | 7 | 2018 | 147 | 0.320 |
Why?
|
| Acetaminophen | 1 | 2009 | 184 | 0.320 |
Why?
|
| Tonsillectomy | 2 | 2020 | 50 | 0.320 |
Why?
|
| Quality of Health Care | 2 | 2016 | 470 | 0.320 |
Why?
|
| Child Behavior | 5 | 2016 | 204 | 0.320 |
Why?
|
| Food | 3 | 2016 | 113 | 0.320 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 1 | 2009 | 283 | 0.310 |
Why?
|
| Weaning | 1 | 2006 | 46 | 0.310 |
Why?
|
| Comorbidity | 10 | 2017 | 1141 | 0.310 |
Why?
|
| Nutrition Assessment | 3 | 2015 | 55 | 0.310 |
Why?
|
| Anorexia Nervosa | 3 | 2006 | 89 | 0.310 |
Why?
|
| Hyperinsulinism | 4 | 2011 | 85 | 0.310 |
Why?
|
| Epigenesis, Genetic | 1 | 2009 | 339 | 0.310 |
Why?
|
| Bronchopulmonary Dysplasia | 1 | 2009 | 210 | 0.310 |
Why?
|
| Smoking | 7 | 2016 | 1174 | 0.310 |
Why?
|
| Quality of Life | 4 | 2009 | 1511 | 0.310 |
Why?
|
| Motor Activity | 8 | 2018 | 550 | 0.310 |
Why?
|
| Infant Formula | 1 | 2006 | 48 | 0.300 |
Why?
|
| Self Report | 3 | 2020 | 481 | 0.300 |
Why?
|
| Maternal Behavior | 1 | 2006 | 63 | 0.300 |
Why?
|
| Pain | 2 | 2009 | 556 | 0.300 |
Why?
|
| Health Surveys | 7 | 2020 | 344 | 0.300 |
Why?
|
| Myocardium | 2 | 2008 | 789 | 0.300 |
Why?
|
| Brain | 4 | 2018 | 1950 | 0.300 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 5 | 2017 | 284 | 0.290 |
Why?
|
| Pain Measurement | 4 | 2013 | 392 | 0.290 |
Why?
|
| Apolipoproteins B | 3 | 2014 | 42 | 0.290 |
Why?
|
| Phosphorus | 1 | 2005 | 63 | 0.290 |
Why?
|
| Child Nutritional Physiological Phenomena | 5 | 2016 | 66 | 0.290 |
Why?
|
| Bariatrics | 1 | 2004 | 1 | 0.290 |
Why?
|
| Mental Recall | 2 | 2013 | 141 | 0.290 |
Why?
|
| Somatoform Disorders | 1 | 2004 | 28 | 0.290 |
Why?
|
| Beriberi | 1 | 2004 | 2 | 0.290 |
Why?
|
| Psychology, Child | 1 | 2004 | 38 | 0.280 |
Why?
|
| Models, Statistical | 6 | 2013 | 477 | 0.280 |
Why?
|
| Insulin | 9 | 2020 | 1537 | 0.280 |
Why?
|
| Psychology, Adolescent | 1 | 2004 | 53 | 0.280 |
Why?
|
| Family | 2 | 2007 | 429 | 0.280 |
Why?
|
| Self Concept | 4 | 2007 | 144 | 0.270 |
Why?
|
| Primary Health Care | 4 | 2015 | 1058 | 0.270 |
Why?
|
| Kidney Diseases | 3 | 2006 | 280 | 0.270 |
Why?
|
| Stroke | 7 | 2019 | 695 | 0.270 |
Why?
|
| Kidney Transplantation | 2 | 2004 | 248 | 0.270 |
Why?
|
| Patient Dropouts | 1 | 2004 | 50 | 0.270 |
Why?
|
| Organ Size | 3 | 2010 | 360 | 0.270 |
Why?
|
| Life Change Events | 1 | 2004 | 102 | 0.270 |
Why?
|
| Renal Dialysis | 6 | 2005 | 244 | 0.270 |
Why?
|
| Eating | 4 | 2017 | 231 | 0.270 |
Why?
|
| Stress, Psychological | 2 | 2004 | 816 | 0.260 |
Why?
|
| Abdominal Cavity | 1 | 2003 | 5 | 0.260 |
Why?
|
| Indomethacin | 2 | 2013 | 63 | 0.260 |
Why?
|
| Sensitivity and Specificity | 7 | 2021 | 1394 | 0.260 |
Why?
|
| Guideline Adherence | 4 | 2017 | 382 | 0.250 |
Why?
|
| Physicians | 2 | 2008 | 511 | 0.250 |
Why?
|
| Health Policy | 3 | 2013 | 233 | 0.250 |
Why?
|
| Hypoglycemic Agents | 1 | 2009 | 714 | 0.250 |
Why?
|
| Phantoms, Imaging | 1 | 2003 | 93 | 0.250 |
Why?
|
| Polysomnography | 6 | 2012 | 144 | 0.250 |
Why?
|
| Menarche | 4 | 2018 | 31 | 0.240 |
Why?
|
| Aging | 6 | 2000 | 1238 | 0.240 |
Why?
|
| Retrospective Studies | 22 | 2019 | 8051 | 0.240 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2006 | 322 | 0.240 |
Why?
|
| White Coat Hypertension | 1 | 2021 | 1 | 0.240 |
Why?
|
| Masked Hypertension | 1 | 2021 | 1 | 0.240 |
Why?
|
| Terminology as Topic | 3 | 2017 | 156 | 0.230 |
Why?
|
| Contraceptives, Oral | 1 | 2001 | 26 | 0.230 |
Why?
|
| Nicardipine | 1 | 2001 | 6 | 0.230 |
Why?
|
| Analgesics, Opioid | 3 | 2016 | 481 | 0.230 |
Why?
|
| Nifedipine | 1 | 2001 | 24 | 0.230 |
Why?
|
| Cluster Analysis | 2 | 2015 | 353 | 0.230 |
Why?
|
| Oligomenorrhea | 2 | 2011 | 4 | 0.230 |
Why?
|
| High Fructose Corn Syrup | 2 | 2018 | 6 | 0.220 |
Why?
|
| Societies, Medical | 4 | 2020 | 578 | 0.220 |
Why?
|
| Myocardial Contraction | 11 | 2004 | 283 | 0.220 |
Why?
|
| Nervous System Diseases | 1 | 2003 | 183 | 0.220 |
Why?
|
| Linear Models | 8 | 2013 | 632 | 0.220 |
Why?
|
| Whole Grains | 1 | 2020 | 2 | 0.220 |
Why?
|
| Risk | 8 | 2012 | 697 | 0.220 |
Why?
|
| Thinness | 2 | 2015 | 62 | 0.220 |
Why?
|
| Graft Rejection | 3 | 1997 | 386 | 0.220 |
Why?
|
| Weight Gain | 3 | 2011 | 361 | 0.210 |
Why?
|
| Reproducibility of Results | 9 | 2015 | 2058 | 0.210 |
Why?
|
| Disease Outbreaks | 1 | 2002 | 195 | 0.210 |
Why?
|
| Epidemiologic Methods | 3 | 1996 | 54 | 0.210 |
Why?
|
| Social Justice | 1 | 2020 | 34 | 0.210 |
Why?
|
| Breast Implants | 2 | 1997 | 9 | 0.210 |
Why?
|
| Silicones | 2 | 1997 | 19 | 0.210 |
Why?
|
| Program Evaluation | 1 | 2004 | 614 | 0.210 |
Why?
|
| Microbiological Techniques | 1 | 2020 | 25 | 0.210 |
Why?
|
| Dairy Products | 2 | 2012 | 19 | 0.210 |
Why?
|
| Asymptomatic Diseases | 1 | 2020 | 48 | 0.210 |
Why?
|
| Equipment Contamination | 1 | 2020 | 38 | 0.210 |
Why?
|
| Calcium | 1 | 2005 | 857 | 0.210 |
Why?
|
| Placebos | 3 | 2009 | 140 | 0.200 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2003 | 387 | 0.200 |
Why?
|
| Sphygmomanometers | 2 | 2012 | 7 | 0.200 |
Why?
|
| Biomedical Research | 2 | 2019 | 441 | 0.200 |
Why?
|
| Cardiac Surgical Procedures | 2 | 2018 | 318 | 0.200 |
Why?
|
| Drug Administration Schedule | 5 | 2016 | 561 | 0.200 |
Why?
|
| Sexual Maturation | 2 | 2018 | 41 | 0.200 |
Why?
|
| Racism | 1 | 2020 | 48 | 0.200 |
Why?
|
| Volunteers | 1 | 2019 | 22 | 0.200 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2003 | 525 | 0.200 |
Why?
|
| Parents | 3 | 2018 | 767 | 0.200 |
Why?
|
| Image Enhancement | 2 | 1997 | 146 | 0.200 |
Why?
|
| Donor Selection | 1 | 2019 | 41 | 0.190 |
Why?
|
| Puberty, Precocious | 1 | 2018 | 13 | 0.190 |
Why?
|
| Receptors, Opioid, mu | 2 | 2016 | 52 | 0.190 |
Why?
|
| Pharmacology | 1 | 2018 | 5 | 0.190 |
Why?
|
| Postoperative Complications | 6 | 2006 | 1517 | 0.190 |
Why?
|
| Diabetic Neuropathies | 1 | 2019 | 60 | 0.190 |
Why?
|
| Prenatal Exposure Delayed Effects | 4 | 2018 | 344 | 0.190 |
Why?
|
| Glutathione | 1 | 1999 | 265 | 0.180 |
Why?
|
| Skinfold Thickness | 3 | 2009 | 34 | 0.180 |
Why?
|
| Bupropion | 1 | 2018 | 28 | 0.180 |
Why?
|
| Antidepressive Agents | 1 | 2019 | 143 | 0.180 |
Why?
|
| Endothelium, Vascular | 5 | 2018 | 647 | 0.180 |
Why?
|
| Biochemistry | 1 | 2018 | 26 | 0.180 |
Why?
|
| Coronary Vessels | 2 | 2018 | 193 | 0.180 |
Why?
|
| Health Personnel | 3 | 2013 | 337 | 0.180 |
Why?
|
| Pregnancy in Diabetics | 1 | 2018 | 47 | 0.180 |
Why?
|
| Pilot Projects | 2 | 2020 | 1046 | 0.180 |
Why?
|
| Clinical Trials as Topic | 6 | 2007 | 721 | 0.180 |
Why?
|
| Education, Medical, Continuing | 2 | 2016 | 97 | 0.180 |
Why?
|
| Lipoproteins | 7 | 2010 | 124 | 0.180 |
Why?
|
| Sodium, Dietary | 2 | 2015 | 30 | 0.180 |
Why?
|
| Electrocardiography | 6 | 2009 | 457 | 0.180 |
Why?
|
| Naltrexone | 1 | 2018 | 64 | 0.180 |
Why?
|
| Ultrasonography | 8 | 2011 | 569 | 0.180 |
Why?
|
| Patient Selection | 3 | 2006 | 479 | 0.180 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2019 | 387 | 0.180 |
Why?
|
| Heart Transplantation | 4 | 2006 | 508 | 0.180 |
Why?
|
| Portion Size | 1 | 2017 | 6 | 0.170 |
Why?
|
| Insurance, Health | 2 | 2009 | 164 | 0.170 |
Why?
|
| Pulmonary Valve Stenosis | 1 | 1997 | 19 | 0.170 |
Why?
|
| Prognosis | 6 | 2019 | 2491 | 0.170 |
Why?
|
| Role | 1 | 1997 | 26 | 0.170 |
Why?
|
| Heart Diseases | 2 | 2004 | 257 | 0.170 |
Why?
|
| Mindfulness | 1 | 2018 | 69 | 0.170 |
Why?
|
| C-Reactive Protein | 2 | 2012 | 252 | 0.170 |
Why?
|
| Anxiety Disorders | 1 | 2019 | 206 | 0.170 |
Why?
|
| Sex Hormone-Binding Globulin | 3 | 2012 | 43 | 0.170 |
Why?
|
| Disease Susceptibility | 2 | 2009 | 275 | 0.170 |
Why?
|
| World Health Organization | 3 | 2014 | 88 | 0.170 |
Why?
|
| Transition to Adult Care | 2 | 2015 | 30 | 0.170 |
Why?
|
| Mammaplasty | 1 | 1997 | 35 | 0.170 |
Why?
|
| History, 20th Century | 3 | 2019 | 229 | 0.170 |
Why?
|
| Toothache | 1 | 2016 | 4 | 0.170 |
Why?
|
| Health Education | 4 | 2013 | 221 | 0.160 |
Why?
|
| Adolescent Nutritional Physiological Phenomena | 4 | 2016 | 13 | 0.160 |
Why?
|
| Acute Disease | 2 | 2009 | 721 | 0.160 |
Why?
|
| Reference Standards | 3 | 2014 | 138 | 0.160 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2005 | 2266 | 0.160 |
Why?
|
| Competency-Based Education | 1 | 2016 | 40 | 0.160 |
Why?
|
| Critical Care | 1 | 2020 | 355 | 0.160 |
Why?
|
| Autonomic Nervous System | 2 | 2013 | 58 | 0.160 |
Why?
|
| Memory, Short-Term | 1 | 2018 | 188 | 0.160 |
Why?
|
| Photoelectron Spectroscopy | 1 | 2016 | 3 | 0.160 |
Why?
|
| Argon | 1 | 2016 | 14 | 0.160 |
Why?
|
| Molar, Third | 3 | 2012 | 4 | 0.160 |
Why?
|
| Spiro Compounds | 1 | 2016 | 6 | 0.160 |
Why?
|
| Injections, Intravenous | 2 | 2013 | 177 | 0.160 |
Why?
|
| Physical Therapy Modalities | 1 | 2018 | 191 | 0.160 |
Why?
|
| Policy Making | 1 | 2016 | 60 | 0.160 |
Why?
|
| Education, Medical, Graduate | 2 | 1997 | 261 | 0.150 |
Why?
|
| Pediatricians | 1 | 2017 | 80 | 0.150 |
Why?
|
| Spectrum Analysis, Raman | 1 | 2016 | 36 | 0.150 |
Why?
|
| Models, Theoretical | 2 | 2009 | 417 | 0.150 |
Why?
|
| Diet Surveys | 3 | 2020 | 56 | 0.150 |
Why?
|
| Tetrahydroisoquinolines | 2 | 2007 | 4 | 0.150 |
Why?
|
| Organ Transplantation | 1 | 1997 | 106 | 0.150 |
Why?
|
| Blood Pressure Monitors | 1 | 2015 | 1 | 0.150 |
Why?
|
| Hypoplastic Left Heart Syndrome | 1 | 1996 | 80 | 0.150 |
Why?
|
| Cognitive Dysfunction | 1 | 2018 | 164 | 0.150 |
Why?
|
| Research | 2 | 2009 | 355 | 0.150 |
Why?
|
| Family Relations | 1 | 2016 | 62 | 0.150 |
Why?
|
| Analgesics | 1 | 2016 | 113 | 0.150 |
Why?
|
| Potassium, Dietary | 1 | 2015 | 9 | 0.150 |
Why?
|
| Microscopy, Atomic Force | 1 | 2016 | 100 | 0.150 |
Why?
|
| Thiophenes | 1 | 2016 | 77 | 0.150 |
Why?
|
| Copper | 1 | 2016 | 94 | 0.150 |
Why?
|
| Learning | 1 | 2018 | 274 | 0.150 |
Why?
|
| Colloids | 1 | 2015 | 46 | 0.150 |
Why?
|
| Fatty Liver | 2 | 2009 | 207 | 0.150 |
Why?
|
| Blood Coagulation | 2 | 2014 | 160 | 0.140 |
Why?
|
| Reye Syndrome | 2 | 1985 | 3 | 0.140 |
Why?
|
| Nutrition Policy | 4 | 2014 | 43 | 0.140 |
Why?
|
| Surface Properties | 1 | 2016 | 304 | 0.140 |
Why?
|
| Medical Informatics | 1 | 2016 | 91 | 0.140 |
Why?
|
| Social Welfare | 1 | 2014 | 13 | 0.140 |
Why?
|
| Silicon Dioxide | 1 | 2015 | 67 | 0.140 |
Why?
|
| Executive Function | 1 | 2018 | 289 | 0.140 |
Why?
|
| Evidence-Based Practice | 1 | 2016 | 119 | 0.140 |
Why?
|
| Continuity of Patient Care | 1 | 2016 | 189 | 0.140 |
Why?
|
| Salicylates | 2 | 1985 | 19 | 0.140 |
Why?
|
| Preventive Health Services | 2 | 2017 | 98 | 0.140 |
Why?
|
| Chronic Disease | 4 | 2017 | 1154 | 0.140 |
Why?
|
| Accelerometry | 1 | 2014 | 44 | 0.140 |
Why?
|
| Phenotype | 2 | 2019 | 2163 | 0.140 |
Why?
|
| Socioeconomic Factors | 3 | 2015 | 802 | 0.140 |
Why?
|
| Eyelashes | 1 | 2014 | 2 | 0.140 |
Why?
|
| Television | 2 | 2019 | 52 | 0.140 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 1 | 2017 | 178 | 0.140 |
Why?
|
| Nanoparticles | 2 | 2015 | 257 | 0.140 |
Why?
|
| Cloprostenol | 1 | 2014 | 11 | 0.140 |
Why?
|
| Burns | 3 | 1993 | 147 | 0.140 |
Why?
|
| Periodicals as Topic | 1 | 1997 | 183 | 0.140 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2017 | 862 | 0.140 |
Why?
|
| Odds Ratio | 6 | 2011 | 768 | 0.140 |
Why?
|
| Child Health Services | 2 | 2016 | 136 | 0.140 |
Why?
|
| Hyperglycemia | 2 | 2014 | 245 | 0.140 |
Why?
|
| Family Practice | 2 | 2003 | 345 | 0.140 |
Why?
|
| Ophthalmic Solutions | 1 | 2014 | 40 | 0.140 |
Why?
|
| Fructose | 1 | 2015 | 137 | 0.130 |
Why?
|
| Child Health | 1 | 2015 | 69 | 0.130 |
Why?
|
| Diabetic Cardiomyopathies | 1 | 2014 | 23 | 0.130 |
Why?
|
| Fluorescent Dyes | 1 | 2015 | 213 | 0.130 |
Why?
|
| Fibrinogen | 1 | 2014 | 117 | 0.130 |
Why?
|
| Personality Inventory | 2 | 1997 | 99 | 0.130 |
Why?
|
| Tachycardia, Supraventricular | 1 | 1994 | 34 | 0.130 |
Why?
|
| Amides | 1 | 2014 | 62 | 0.130 |
Why?
|
| Elasticity | 2 | 2011 | 145 | 0.130 |
Why?
|
| Melatonin | 2 | 2004 | 77 | 0.130 |
Why?
|
| Clinical Competence | 2 | 2016 | 641 | 0.130 |
Why?
|
| Surface-Active Agents | 2 | 2015 | 74 | 0.130 |
Why?
|
| Administration, Oral | 3 | 2012 | 588 | 0.130 |
Why?
|
| Administrative Personnel | 1 | 2013 | 26 | 0.130 |
Why?
|
| Suburban Population | 2 | 2005 | 8 | 0.130 |
Why?
|
| Sex Characteristics | 4 | 1997 | 471 | 0.130 |
Why?
|
| Precision Medicine | 1 | 2016 | 228 | 0.130 |
Why?
|
| History, 21st Century | 2 | 2018 | 156 | 0.130 |
Why?
|
| Seasons | 1 | 2014 | 297 | 0.130 |
Why?
|
| Plasma | 1 | 2014 | 162 | 0.130 |
Why?
|
| Patient Education as Topic | 3 | 2012 | 544 | 0.130 |
Why?
|
| Algorithms | 3 | 2009 | 1124 | 0.120 |
Why?
|
| Adenosine | 1 | 1994 | 151 | 0.120 |
Why?
|
| Public Health Practice | 1 | 2013 | 52 | 0.120 |
Why?
|
| Coagulants | 1 | 2012 | 5 | 0.120 |
Why?
|
| Femoral Artery | 1 | 2013 | 115 | 0.120 |
Why?
|
| Nutritional Physiological Phenomena | 3 | 2001 | 43 | 0.120 |
Why?
|
| Infant, Premature | 2 | 1992 | 319 | 0.120 |
Why?
|
| Environmental Microbiology | 1 | 2012 | 30 | 0.120 |
Why?
|
| Epidemiological Monitoring | 1 | 2012 | 37 | 0.120 |
Why?
|
| Poverty | 1 | 2016 | 342 | 0.120 |
Why?
|
| Apolipoprotein A-I | 1 | 2012 | 19 | 0.120 |
Why?
|
| Factor VIII | 1 | 2012 | 33 | 0.120 |
Why?
|
| Baroreflex | 1 | 2012 | 40 | 0.120 |
Why?
|
| Combined Modality Therapy | 5 | 2017 | 864 | 0.120 |
Why?
|
| Blood Coagulation Tests | 1 | 2012 | 45 | 0.120 |
Why?
|
| Suburban Health | 1 | 2012 | 2 | 0.120 |
Why?
|
| Glycemic Index | 1 | 2012 | 13 | 0.120 |
Why?
|
| Mercury | 1 | 2012 | 26 | 0.120 |
Why?
|
| National Health Programs | 1 | 2012 | 19 | 0.120 |
Why?
|
| Polycystic Ovary Syndrome | 2 | 2011 | 131 | 0.120 |
Why?
|
| Animals | 6 | 2019 | 25325 | 0.120 |
Why?
|
| Salaries and Fringe Benefits | 1 | 2012 | 20 | 0.120 |
Why?
|
| Brain Ischemia | 2 | 2019 | 202 | 0.120 |
Why?
|
| Urban Health | 1 | 2012 | 70 | 0.120 |
Why?
|
| Blood Vessels | 2 | 2005 | 135 | 0.120 |
Why?
|
| Observer Variation | 5 | 2012 | 220 | 0.120 |
Why?
|
| Electronic Health Records | 2 | 2017 | 486 | 0.120 |
Why?
|
| Ligation | 2 | 2009 | 73 | 0.120 |
Why?
|
| Forecasting | 3 | 2015 | 293 | 0.120 |
Why?
|
| Cyclooxygenase Inhibitors | 2 | 2003 | 60 | 0.120 |
Why?
|
| Least-Squares Analysis | 2 | 2008 | 52 | 0.120 |
Why?
|
| Community Health Services | 1 | 2013 | 145 | 0.120 |
Why?
|
| Meat | 2 | 2010 | 47 | 0.110 |
Why?
|
| Infection Control | 1 | 2012 | 106 | 0.110 |
Why?
|
| Ventricular Function | 3 | 2000 | 53 | 0.110 |
Why?
|
| Patient-Centered Care | 1 | 2015 | 319 | 0.110 |
Why?
|
| LDL-Receptor Related Proteins | 1 | 2011 | 4 | 0.110 |
Why?
|
| Principal Component Analysis | 1 | 2012 | 148 | 0.110 |
Why?
|
| Household Products | 1 | 1991 | 5 | 0.110 |
Why?
|
| Glucose | 1 | 2015 | 580 | 0.110 |
Why?
|
| Detergents | 1 | 1991 | 37 | 0.110 |
Why?
|
| National Institutes of Health (U.S.) | 5 | 2016 | 76 | 0.110 |
Why?
|
| Connective Tissue Diseases | 2 | 1994 | 34 | 0.110 |
Why?
|
| Household Articles | 1 | 1991 | 24 | 0.110 |
Why?
|
| Early Diagnosis | 1 | 2012 | 188 | 0.110 |
Why?
|
| Coronary Artery Disease | 2 | 2011 | 508 | 0.110 |
Why?
|
| Menstrual Cycle | 1 | 2011 | 77 | 0.110 |
Why?
|
| Body Fat Distribution | 1 | 2010 | 36 | 0.110 |
Why?
|
| Obesity, Abdominal | 1 | 2010 | 26 | 0.110 |
Why?
|
| Referral and Consultation | 2 | 2020 | 470 | 0.110 |
Why?
|
| Carotid Artery Diseases | 1 | 2010 | 39 | 0.110 |
Why?
|
| Social Class | 2 | 2018 | 167 | 0.110 |
Why?
|
| Cross Infection | 1 | 2012 | 147 | 0.110 |
Why?
|
| Finland | 3 | 2019 | 44 | 0.110 |
Why?
|
| Aged, 80 and over | 5 | 2013 | 4819 | 0.110 |
Why?
|
| Drug Delivery Systems | 1 | 2013 | 243 | 0.110 |
Why?
|
| Retinal Vessels | 1 | 1991 | 47 | 0.110 |
Why?
|
| Cardiovascular Physiological Phenomena | 1 | 2010 | 35 | 0.100 |
Why?
|
| Heart Failure | 6 | 2008 | 1342 | 0.100 |
Why?
|
| Australia | 3 | 2019 | 158 | 0.100 |
Why?
|
| Peritoneal Dialysis | 2 | 2001 | 54 | 0.100 |
Why?
|
| Silver Sulfadiazine | 1 | 1989 | 1 | 0.100 |
Why?
|
| Sulfadiazine | 1 | 1989 | 3 | 0.100 |
Why?
|
| Cost-Benefit Analysis | 1 | 2012 | 349 | 0.100 |
Why?
|
| Acrylates | 1 | 1989 | 28 | 0.100 |
Why?
|
| Dimethyl Sulfoxide | 1 | 1989 | 39 | 0.100 |
Why?
|
| Dosage Forms | 1 | 2009 | 5 | 0.100 |
Why?
|
| Basal Metabolism | 2 | 2002 | 40 | 0.100 |
Why?
|
| Nutritional Requirements | 2 | 2007 | 54 | 0.100 |
Why?
|
| Epiphyses, Slipped | 1 | 2009 | 3 | 0.100 |
Why?
|
| Carotid Stenosis | 1 | 2009 | 36 | 0.100 |
Why?
|
| Tooth, Impacted | 1 | 2009 | 4 | 0.100 |
Why?
|
| Therapeutic Equivalency | 1 | 2009 | 16 | 0.100 |
Why?
|
| Homeostasis | 2 | 2009 | 410 | 0.100 |
Why?
|
| Stroke Volume | 3 | 2020 | 320 | 0.100 |
Why?
|
| Health Care Costs | 1 | 2012 | 266 | 0.100 |
Why?
|
| Methacrylates | 1 | 1989 | 73 | 0.100 |
Why?
|
| Diet Therapy | 2 | 2017 | 24 | 0.100 |
Why?
|
| Retinol-Binding Proteins, Plasma | 1 | 2008 | 3 | 0.100 |
Why?
|
| Survivors | 1 | 2011 | 274 | 0.100 |
Why?
|
| Calcinosis | 1 | 2011 | 203 | 0.090 |
Why?
|
| Leadership | 1 | 2012 | 222 | 0.090 |
Why?
|
| Sample Size | 1 | 2009 | 76 | 0.090 |
Why?
|
| Sleep Apnea, Central | 1 | 2008 | 5 | 0.090 |
Why?
|
| Diagnostic Errors | 2 | 2007 | 105 | 0.090 |
Why?
|
| Sulfonamides | 3 | 2013 | 331 | 0.090 |
Why?
|
| Drug Combinations | 3 | 2018 | 228 | 0.090 |
Why?
|
| Decision Support Techniques | 1 | 2012 | 286 | 0.090 |
Why?
|
| Fatty Acids | 2 | 2001 | 294 | 0.090 |
Why?
|
| Internship and Residency | 3 | 2007 | 680 | 0.090 |
Why?
|
| Osteoporosis | 1 | 2010 | 139 | 0.090 |
Why?
|
| Congresses as Topic | 1 | 2009 | 140 | 0.090 |
Why?
|
| Intracranial Hemorrhages | 1 | 2008 | 50 | 0.090 |
Why?
|
| Oxygen Consumption | 1 | 2010 | 449 | 0.090 |
Why?
|
| Drug Utilization | 1 | 2009 | 139 | 0.090 |
Why?
|
| Digestive System Diseases | 1 | 2008 | 20 | 0.090 |
Why?
|
| Age Distribution | 2 | 2015 | 265 | 0.090 |
Why?
|
| Prescription Drugs | 1 | 2009 | 82 | 0.090 |
Why?
|
| Arousal | 2 | 2004 | 141 | 0.090 |
Why?
|
| Ifosfamide | 1 | 2007 | 22 | 0.090 |
Why?
|
| Dioxoles | 1 | 2007 | 5 | 0.090 |
Why?
|
| Health Planning Councils | 1 | 2007 | 3 | 0.090 |
Why?
|
| Blood Flow Velocity | 5 | 2011 | 249 | 0.090 |
Why?
|
| Diagnostic Imaging | 1 | 2009 | 181 | 0.090 |
Why?
|
| Models, Animal | 1 | 2009 | 264 | 0.090 |
Why?
|
| Anthracyclines | 1 | 2007 | 17 | 0.090 |
Why?
|
| Perioperative Care | 2 | 2006 | 81 | 0.090 |
Why?
|
| Signal Detection, Psychological | 1 | 2007 | 16 | 0.090 |
Why?
|
| Hypothalamic Diseases | 1 | 2007 | 16 | 0.090 |
Why?
|
| Physical Examination | 1 | 2009 | 188 | 0.090 |
Why?
|
| Cerebrovascular Disorders | 3 | 1982 | 68 | 0.090 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2009 | 186 | 0.090 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2007 | 45 | 0.090 |
Why?
|
| Cardiovascular Abnormalities | 1 | 2007 | 9 | 0.090 |
Why?
|
| Texas | 1 | 2007 | 134 | 0.090 |
Why?
|
| Postoperative Period | 1 | 2008 | 200 | 0.090 |
Why?
|
| Informed Consent | 2 | 2006 | 103 | 0.090 |
Why?
|
| Syndrome | 2 | 2004 | 229 | 0.080 |
Why?
|
| Waiting Lists | 1 | 2008 | 85 | 0.080 |
Why?
|
| Trace Elements | 1 | 2007 | 28 | 0.080 |
Why?
|
| Craniopharyngioma | 1 | 2007 | 35 | 0.080 |
Why?
|
| Endocardium | 2 | 1997 | 27 | 0.080 |
Why?
|
| Micronutrients | 1 | 2007 | 45 | 0.080 |
Why?
|
| Health Knowledge, Attitudes, Practice | 3 | 2012 | 858 | 0.080 |
Why?
|
| Drug Therapy, Combination | 2 | 2008 | 730 | 0.080 |
Why?
|
| Pituitary Neoplasms | 1 | 2007 | 108 | 0.080 |
Why?
|
| Liver Transplantation | 1 | 2011 | 499 | 0.080 |
Why?
|
| Sarcoma | 1 | 2007 | 91 | 0.080 |
Why?
|
| Sex Distribution | 2 | 2010 | 265 | 0.080 |
Why?
|
| Drinking Behavior | 1 | 2006 | 12 | 0.080 |
Why?
|
| Vitamins | 1 | 2007 | 109 | 0.080 |
Why?
|
| Healthy People Programs | 1 | 2006 | 4 | 0.080 |
Why?
|
| Gastroenterology | 1 | 2008 | 119 | 0.080 |
Why?
|
| Publication Bias | 1 | 2006 | 30 | 0.080 |
Why?
|
| Celecoxib | 3 | 2013 | 32 | 0.080 |
Why?
|
| Disorders of Excessive Somnolence | 1 | 2006 | 27 | 0.080 |
Why?
|
| Epidemiologic Studies | 1 | 2005 | 37 | 0.080 |
Why?
|
| Virginia | 1 | 2005 | 42 | 0.080 |
Why?
|
| Peer Review, Research | 1 | 2006 | 32 | 0.080 |
Why?
|
| Social Environment | 1 | 2007 | 244 | 0.080 |
Why?
|
| Infant Food | 1 | 2006 | 54 | 0.080 |
Why?
|
| Hospitals, Pediatric | 3 | 2005 | 361 | 0.080 |
Why?
|
| Echocardiography, Doppler | 3 | 1998 | 89 | 0.080 |
Why?
|
| Sulfones | 2 | 2003 | 80 | 0.070 |
Why?
|
| Anastomosis, Roux-en-Y | 1 | 2005 | 21 | 0.070 |
Why?
|
| Polyethylene Glycols | 1 | 1989 | 412 | 0.070 |
Why?
|
| Serum Amyloid A Protein | 1 | 2005 | 20 | 0.070 |
Why?
|
| Genetic Testing | 2 | 2021 | 258 | 0.070 |
Why?
|
| Reward | 2 | 2018 | 150 | 0.070 |
Why?
|
| Hypercalcemia | 1 | 1985 | 16 | 0.070 |
Why?
|
| Recurrence | 2 | 2004 | 719 | 0.070 |
Why?
|
| Infant Nutritional Physiological Phenomena | 1 | 2006 | 97 | 0.070 |
Why?
|
| Hyperphagia | 1 | 2004 | 11 | 0.070 |
Why?
|
| Milk, Human | 1 | 2006 | 99 | 0.070 |
Why?
|
| Smoke | 1 | 2005 | 74 | 0.070 |
Why?
|
| Personality Assessment | 1 | 2004 | 69 | 0.070 |
Why?
|
| Urban Population | 2 | 2005 | 305 | 0.070 |
Why?
|
| Haplotypes | 1 | 2006 | 380 | 0.070 |
Why?
|
| Cross-Over Studies | 3 | 2012 | 327 | 0.070 |
Why?
|
| Internal-External Control | 1 | 2004 | 66 | 0.070 |
Why?
|
| Compliance | 1 | 2004 | 35 | 0.070 |
Why?
|
| Cardiac Volume | 1 | 1984 | 7 | 0.070 |
Why?
|
| Parental Consent | 1 | 2004 | 19 | 0.070 |
Why?
|
| Mental Competency | 1 | 2004 | 27 | 0.070 |
Why?
|
| Likelihood Functions | 1 | 2004 | 121 | 0.070 |
Why?
|
| Glomerular Filtration Rate | 1 | 2006 | 421 | 0.070 |
Why?
|
| Oxyhemoglobins | 1 | 2004 | 14 | 0.070 |
Why?
|
| Arm | 1 | 2004 | 65 | 0.070 |
Why?
|
| Twins | 1 | 2005 | 210 | 0.070 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2004 | 66 | 0.070 |
Why?
|
| Myocardial Ischemia | 2 | 2008 | 203 | 0.070 |
Why?
|
| Diagnosis, Differential | 4 | 2005 | 996 | 0.070 |
Why?
|
| Blood Gas Analysis | 1 | 2004 | 67 | 0.070 |
Why?
|
| Contraception | 2 | 2011 | 79 | 0.070 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 1 | 2004 | 193 | 0.070 |
Why?
|
| Minority Groups | 1 | 2005 | 137 | 0.070 |
Why?
|
| Cardiac Pacing, Artificial | 1 | 1984 | 64 | 0.070 |
Why?
|
| Mother-Child Relations | 1 | 2004 | 88 | 0.070 |
Why?
|
| ROC Curve | 2 | 2011 | 374 | 0.060 |
Why?
|
| Vascular Diseases | 1 | 1985 | 134 | 0.060 |
Why?
|
| Pyrazoles | 3 | 2013 | 262 | 0.060 |
Why?
|
| Leg | 1 | 2004 | 177 | 0.060 |
Why?
|
| Epidemiology | 1 | 1983 | 17 | 0.060 |
Why?
|
| Infant, Premature, Diseases | 1 | 1984 | 65 | 0.060 |
Why?
|
| Community Health Planning | 1 | 2003 | 20 | 0.060 |
Why?
|
| Isoquinolines | 1 | 2003 | 36 | 0.060 |
Why?
|
| Behavior Therapy | 1 | 2005 | 166 | 0.060 |
Why?
|
| Analgesia | 1 | 2003 | 67 | 0.060 |
Why?
|
| Asian Americans | 2 | 2005 | 51 | 0.060 |
Why?
|
| Delayed-Action Preparations | 2 | 2016 | 119 | 0.060 |
Why?
|
| Infant Welfare | 1 | 2002 | 6 | 0.060 |
Why?
|
| School Health Services | 1 | 2004 | 123 | 0.060 |
Why?
|
| Models, Biological | 1 | 2009 | 1260 | 0.060 |
Why?
|
| Intracranial Arteriosclerosis | 1 | 1982 | 4 | 0.060 |
Why?
|
| Registries | 2 | 2007 | 1281 | 0.060 |
Why?
|
| Self-Help Groups | 2 | 2005 | 21 | 0.060 |
Why?
|
| Probability | 2 | 2000 | 209 | 0.060 |
Why?
|
| Health Services Accessibility | 1 | 2008 | 555 | 0.060 |
Why?
|
| Aortic Valve Stenosis | 1 | 1985 | 163 | 0.060 |
Why?
|
| Adaptation, Physiological | 1 | 2005 | 369 | 0.060 |
Why?
|
| Statistics, Nonparametric | 2 | 2014 | 324 | 0.060 |
Why?
|
| Academies and Institutes | 1 | 2021 | 31 | 0.060 |
Why?
|
| Heart Septal Defects, Ventricular | 2 | 1991 | 29 | 0.060 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2018 | 2177 | 0.060 |
Why?
|
| Rest | 1 | 2001 | 81 | 0.060 |
Why?
|
| Endpoint Determination | 1 | 2001 | 47 | 0.060 |
Why?
|
| Pulsatile Flow | 2 | 2011 | 38 | 0.060 |
Why?
|
| Hypertrichosis | 1 | 2001 | 3 | 0.060 |
Why?
|
| Lip | 1 | 2001 | 13 | 0.060 |
Why?
|
| Membrane Transport Proteins | 1 | 2002 | 109 | 0.060 |
Why?
|
| Medicaid | 1 | 2004 | 274 | 0.050 |
Why?
|
| Rats | 1 | 2009 | 4631 | 0.050 |
Why?
|
| Health | 1 | 2001 | 65 | 0.050 |
Why?
|
| Nutritional Sciences | 1 | 2001 | 27 | 0.050 |
Why?
|
| Religion and Psychology | 1 | 1980 | 19 | 0.050 |
Why?
|
| Hair | 1 | 2001 | 47 | 0.050 |
Why?
|
| Pyridines | 1 | 2003 | 332 | 0.050 |
Why?
|
| Mitochondrial Proteins | 1 | 2002 | 173 | 0.050 |
Why?
|
| Bacteria, Aerobic | 1 | 2020 | 5 | 0.050 |
Why?
|
| Hypertriglyceridemia | 2 | 2011 | 29 | 0.050 |
Why?
|
| Decontamination | 1 | 2020 | 10 | 0.050 |
Why?
|
| Attitude to Death | 1 | 1980 | 46 | 0.050 |
Why?
|
| Chi-Square Distribution | 3 | 2014 | 399 | 0.050 |
Why?
|
| Gastric Emptying | 1 | 2000 | 22 | 0.050 |
Why?
|
| RNA, Messenger | 2 | 2018 | 2051 | 0.050 |
Why?
|
| Exercise Therapy | 2 | 2017 | 244 | 0.050 |
Why?
|
| Cardiomegaly | 2 | 1991 | 134 | 0.050 |
Why?
|
| Stomach | 1 | 2000 | 71 | 0.050 |
Why?
|
| Extracorporeal Membrane Oxygenation | 2 | 1993 | 146 | 0.050 |
Why?
|
| Autonomic Nervous System Diseases | 1 | 2019 | 16 | 0.050 |
Why?
|
| Homocysteine | 1 | 1999 | 95 | 0.050 |
Why?
|
| Lactones | 1 | 1999 | 42 | 0.050 |
Why?
|
| Association | 1 | 2019 | 9 | 0.050 |
Why?
|
| Oxidative Stress | 2 | 2008 | 873 | 0.050 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2000 | 101 | 0.050 |
Why?
|
| Polyradiculoneuropathy | 1 | 1998 | 3 | 0.050 |
Why?
|
| Dimensional Measurement Accuracy | 1 | 2018 | 7 | 0.050 |
Why?
|
| Attitude of Health Personnel | 2 | 2017 | 716 | 0.050 |
Why?
|
| Coronary Artery Bypass | 1 | 2000 | 203 | 0.050 |
Why?
|
| Switzerland | 1 | 2018 | 14 | 0.050 |
Why?
|
| Neuropharmacology | 1 | 2018 | 4 | 0.050 |
Why?
|
| England | 1 | 2018 | 43 | 0.050 |
Why?
|
| Postmenopause | 1 | 2000 | 243 | 0.050 |
Why?
|
| Occupational Health | 2 | 2013 | 125 | 0.050 |
Why?
|
| Endothelins | 1 | 2018 | 47 | 0.050 |
Why?
|
| Sulfhydryl Compounds | 1 | 1999 | 134 | 0.050 |
Why?
|
| Metabolic Clearance Rate | 2 | 2012 | 97 | 0.050 |
Why?
|
| Carrier Proteins | 1 | 2002 | 586 | 0.040 |
Why?
|
| Half-Life | 2 | 2012 | 119 | 0.040 |
Why?
|
| Liver | 3 | 2015 | 1308 | 0.040 |
Why?
|
| Self Administration | 1 | 2018 | 101 | 0.040 |
Why?
|
| Lipoproteins, LDL | 3 | 2008 | 108 | 0.040 |
Why?
|
| Area Under Curve | 2 | 2012 | 246 | 0.040 |
Why?
|
| Glycemic Load | 1 | 2017 | 1 | 0.040 |
Why?
|
| Morphine | 2 | 2016 | 133 | 0.040 |
Why?
|
| Random Allocation | 1 | 2018 | 289 | 0.040 |
Why?
|
| Retinal Diseases | 2 | 1990 | 60 | 0.040 |
Why?
|
| Rheumatic Diseases | 1 | 1997 | 33 | 0.040 |
Why?
|
| Lipoproteins, HDL | 2 | 2016 | 67 | 0.040 |
Why?
|
| Oxidation-Reduction | 1 | 1999 | 737 | 0.040 |
Why?
|
| Self-Control | 1 | 2017 | 41 | 0.040 |
Why?
|
| Tablets | 1 | 2016 | 22 | 0.040 |
Why?
|
| Specialty Boards | 1 | 2016 | 21 | 0.040 |
Why?
|
| Food Safety | 1 | 2016 | 11 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2005 | 1698 | 0.040 |
Why?
|
| Contraindications | 2 | 2007 | 68 | 0.040 |
Why?
|
| Surgical Flaps | 1 | 1997 | 83 | 0.040 |
Why?
|
| Munchausen Syndrome by Proxy | 1 | 1996 | 2 | 0.040 |
Why?
|
| Ipecac | 1 | 1996 | 5 | 0.040 |
Why?
|
| Dietary Proteins | 2 | 2011 | 79 | 0.040 |
Why?
|
| Gastrointestinal Agents | 1 | 2017 | 47 | 0.040 |
Why?
|
| Calcium, Dietary | 2 | 2007 | 41 | 0.040 |
Why?
|
| Proteins | 1 | 2002 | 707 | 0.040 |
Why?
|
| Automation | 1 | 1996 | 56 | 0.040 |
Why?
|
| Anemia, Sickle Cell | 2 | 2008 | 146 | 0.040 |
Why?
|
| Sodium Chloride | 1 | 1997 | 135 | 0.040 |
Why?
|
| Membrane Proteins | 1 | 2002 | 810 | 0.040 |
Why?
|
| Enzyme Inhibitors | 1 | 1999 | 634 | 0.040 |
Why?
|
| Analysis of Variance | 2 | 2011 | 1089 | 0.040 |
Why?
|
| Drug Interactions | 1 | 1997 | 275 | 0.040 |
Why?
|
| Minority Health | 1 | 2016 | 17 | 0.040 |
Why?
|
| Selection Bias | 1 | 1995 | 25 | 0.040 |
Why?
|
| Reoperation | 1 | 1997 | 376 | 0.040 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2014 | 645 | 0.040 |
Why?
|
| Sodium Dodecyl Sulfate | 1 | 2015 | 13 | 0.040 |
Why?
|
| Professional-Patient Relations | 1 | 2016 | 100 | 0.040 |
Why?
|
| Tobacco Products | 1 | 2016 | 39 | 0.040 |
Why?
|
| Spectrophotometry, Ultraviolet | 1 | 2015 | 59 | 0.040 |
Why?
|
| Immunization | 1 | 1997 | 264 | 0.040 |
Why?
|
| Polysorbates | 1 | 2015 | 37 | 0.040 |
Why?
|
| Anxiety | 1 | 1980 | 553 | 0.040 |
Why?
|
| Drug Prescriptions | 1 | 2017 | 177 | 0.040 |
Why?
|
| Ankle Brachial Index | 1 | 2015 | 26 | 0.040 |
Why?
|
| DNA Methylation | 1 | 2018 | 316 | 0.040 |
Why?
|
| Serum Albumin, Bovine | 1 | 2015 | 50 | 0.040 |
Why?
|
| Immunoassay | 1 | 2015 | 75 | 0.040 |
Why?
|
| Hyperlipoproteinemias | 2 | 2007 | 7 | 0.040 |
Why?
|
| Monitoring, Physiologic | 1 | 1996 | 166 | 0.040 |
Why?
|
| Scattering, Radiation | 1 | 2015 | 87 | 0.040 |
Why?
|
| Growth | 1 | 1995 | 45 | 0.040 |
Why?
|
| Freeze Drying | 1 | 2015 | 113 | 0.040 |
Why?
|
| Ventricular Function, Right | 1 | 1996 | 145 | 0.040 |
Why?
|
| Fatty Acids, Omega-6 | 1 | 2015 | 35 | 0.040 |
Why?
|
| Behavior, Addictive | 1 | 2015 | 56 | 0.040 |
Why?
|
| Breast Diseases | 1 | 1994 | 18 | 0.040 |
Why?
|
| Fontan Procedure | 1 | 1996 | 117 | 0.040 |
Why?
|
| Guidelines as Topic | 2 | 2007 | 206 | 0.040 |
Why?
|
| Receptors, Dopamine D2 | 1 | 2015 | 85 | 0.040 |
Why?
|
| Quinolines | 1 | 2015 | 97 | 0.040 |
Why?
|
| Bimatoprost | 1 | 2014 | 4 | 0.030 |
Why?
|
| Lymphoscintigraphy | 1 | 1994 | 11 | 0.030 |
Why?
|
| Cholesterol, Dietary | 2 | 2007 | 22 | 0.030 |
Why?
|
| Mice | 1 | 2009 | 11250 | 0.030 |
Why?
|
| Nonverbal Communication | 1 | 1994 | 7 | 0.030 |
Why?
|
| Health Status Indicators | 1 | 2015 | 131 | 0.030 |
Why?
|
| International Cooperation | 1 | 2014 | 140 | 0.030 |
Why?
|
| Esthetics | 1 | 2014 | 35 | 0.030 |
Why?
|
| Visual Analog Scale | 1 | 2013 | 21 | 0.030 |
Why?
|
| Particle Size | 1 | 2015 | 305 | 0.030 |
Why?
|
| Capsules | 1 | 2013 | 31 | 0.030 |
Why?
|
| Breast | 1 | 1994 | 103 | 0.030 |
Why?
|
| Heart Block | 1 | 1994 | 31 | 0.030 |
Why?
|
| Neoplasms | 2 | 2006 | 1441 | 0.030 |
Why?
|
| Canada | 2 | 2008 | 237 | 0.030 |
Why?
|
| Interleukin-2 | 1 | 1994 | 285 | 0.030 |
Why?
|
| Confidence Intervals | 2 | 2007 | 253 | 0.030 |
Why?
|
| Cardiomyopathies | 1 | 1996 | 220 | 0.030 |
Why?
|
| Clinical Clerkship | 1 | 1994 | 57 | 0.030 |
Why?
|
| Survival Analysis | 2 | 2010 | 981 | 0.030 |
Why?
|
| Anesthesia, General | 1 | 1993 | 30 | 0.030 |
Why?
|
| Statistics as Topic | 2 | 2004 | 247 | 0.030 |
Why?
|
| MicroRNAs | 1 | 2018 | 455 | 0.030 |
Why?
|
| Fibromyalgia | 1 | 1993 | 37 | 0.030 |
Why?
|
| Cardiac Output, Low | 1 | 1993 | 53 | 0.030 |
Why?
|
| Debridement | 1 | 1993 | 61 | 0.030 |
Why?
|
| Light | 1 | 2015 | 282 | 0.030 |
Why?
|
| Biopsy | 2 | 2006 | 751 | 0.030 |
Why?
|
| Genetic Carrier Screening | 1 | 2012 | 18 | 0.030 |
Why?
|
| Colony Count, Microbial | 1 | 2012 | 56 | 0.030 |
Why?
|
| Hyaluronic Acid | 1 | 1994 | 148 | 0.030 |
Why?
|
| International System of Units | 1 | 2012 | 2 | 0.030 |
Why?
|
| Gene Expression Profiling | 1 | 2018 | 1153 | 0.030 |
Why?
|
| Catheterization | 1 | 1993 | 124 | 0.030 |
Why?
|
| Vulnerable Populations | 1 | 2013 | 85 | 0.030 |
Why?
|
| Fathers | 1 | 2012 | 32 | 0.030 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 1 | 2012 | 68 | 0.030 |
Why?
|
| Radionuclide Imaging | 2 | 2000 | 111 | 0.030 |
Why?
|
| Gravidity | 1 | 2011 | 6 | 0.030 |
Why?
|
| Absorption | 1 | 2012 | 34 | 0.030 |
Why?
|
| Calibration | 1 | 2012 | 100 | 0.030 |
Why?
|
| Goals | 1 | 2013 | 106 | 0.030 |
Why?
|
| Immunoglobulin G | 1 | 2015 | 551 | 0.030 |
Why?
|
| Digoxin | 1 | 1991 | 23 | 0.030 |
Why?
|
| Causality | 1 | 2012 | 73 | 0.030 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2012 | 208 | 0.030 |
Why?
|
| Parity | 1 | 2011 | 76 | 0.030 |
Why?
|
| Emotions | 1 | 2016 | 326 | 0.030 |
Why?
|
| Evaluation Studies as Topic | 3 | 1993 | 167 | 0.030 |
Why?
|
| Hyperaldosteronism | 1 | 2011 | 4 | 0.030 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2012 | 124 | 0.030 |
Why?
|
| Inservice Training | 1 | 2012 | 88 | 0.030 |
Why?
|
| Proprotein Convertases | 1 | 2011 | 8 | 0.030 |
Why?
|
| 2-Hydroxypropyl-beta-cyclodextrin | 1 | 2011 | 7 | 0.030 |
Why?
|
| Fundus Oculi | 1 | 1991 | 36 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2012 | 1756 | 0.030 |
Why?
|
| Radioimmunoassay | 1 | 2011 | 118 | 0.030 |
Why?
|
| Proprotein Convertase 9 | 1 | 2011 | 35 | 0.030 |
Why?
|
| Patient Satisfaction | 1 | 2014 | 417 | 0.030 |
Why?
|
| Medical History Taking | 1 | 1991 | 99 | 0.030 |
Why?
|
| beta-Cyclodextrins | 1 | 2011 | 23 | 0.030 |
Why?
|
| Students, Medical | 1 | 1994 | 180 | 0.030 |
Why?
|
| Actigraphy | 1 | 2011 | 89 | 0.030 |
Why?
|
| Serine Endopeptidases | 1 | 2011 | 78 | 0.030 |
Why?
|
| Homozygote | 1 | 2011 | 154 | 0.030 |
Why?
|
| Photography | 1 | 1991 | 74 | 0.030 |
Why?
|
| Food Handling | 1 | 2010 | 16 | 0.030 |
Why?
|
| Mental Disorders | 1 | 1997 | 679 | 0.030 |
Why?
|
| Smoking Cessation | 1 | 2013 | 266 | 0.030 |
Why?
|
| Health Planning Guidelines | 1 | 2010 | 13 | 0.030 |
Why?
|
| Environment | 1 | 2012 | 279 | 0.030 |
Why?
|
| Head and Neck Neoplasms | 1 | 1994 | 295 | 0.030 |
Why?
|
| Cooking | 1 | 2010 | 30 | 0.030 |
Why?
|
| Type A Personality | 1 | 1989 | 2 | 0.030 |
Why?
|
| Organizational Objectives | 1 | 2010 | 50 | 0.030 |
Why?
|
| Occlusive Dressings | 1 | 1989 | 2 | 0.030 |
Why?
|
| Adhesiveness | 1 | 1989 | 13 | 0.030 |
Why?
|
| Malnutrition | 1 | 2010 | 35 | 0.030 |
Why?
|
| Oscillometry | 1 | 2009 | 21 | 0.030 |
Why?
|
| Drug Evaluation | 1 | 1989 | 60 | 0.030 |
Why?
|
| Manometry | 1 | 2009 | 55 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2018 | 1914 | 0.020 |
Why?
|
| Fistula | 1 | 1989 | 8 | 0.020 |
Why?
|
| Ultrasonography, Doppler | 1 | 2009 | 77 | 0.020 |
Why?
|
| Risk Management | 1 | 2010 | 70 | 0.020 |
Why?
|
| Hemoglobins | 2 | 1989 | 191 | 0.020 |
Why?
|
| Coronary Vessel Anomalies | 1 | 1989 | 22 | 0.020 |
Why?
|
| South Carolina | 1 | 2008 | 20 | 0.020 |
Why?
|
| Consensus Development Conferences as Topic | 1 | 2008 | 28 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2011 | 629 | 0.020 |
Why?
|
| Cardiomyopathy, Dilated | 1 | 1991 | 248 | 0.020 |
Why?
|
| Moyamoya Disease | 1 | 2008 | 10 | 0.020 |
Why?
|
| Psychometrics | 2 | 1989 | 465 | 0.020 |
Why?
|
| Intracranial Embolism | 1 | 2008 | 18 | 0.020 |
Why?
|
| Pulmonary Veins | 1 | 1989 | 64 | 0.020 |
Why?
|
| Nutrition Therapy | 1 | 2008 | 22 | 0.020 |
Why?
|
| Gestational Age | 1 | 2011 | 550 | 0.020 |
Why?
|
| Melanoma | 1 | 1994 | 531 | 0.020 |
Why?
|
| Persistent Fetal Circulation Syndrome | 1 | 1989 | 80 | 0.020 |
Why?
|
| Georgia | 1 | 1988 | 43 | 0.020 |
Why?
|
| Physical Exertion | 1 | 1989 | 180 | 0.020 |
Why?
|
| Risk-Taking | 1 | 2010 | 267 | 0.020 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2009 | 164 | 0.020 |
Why?
|
| Continuous Positive Airway Pressure | 1 | 2008 | 51 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2012 | 820 | 0.020 |
Why?
|
| Sympathetic Nervous System | 1 | 2008 | 137 | 0.020 |
Why?
|
| Medical Audit | 1 | 2008 | 65 | 0.020 |
Why?
|
| Cooperative Behavior | 1 | 2010 | 296 | 0.020 |
Why?
|
| Hypopituitarism | 1 | 2007 | 14 | 0.020 |
Why?
|
| Interpersonal Relations | 2 | 2006 | 235 | 0.020 |
Why?
|
| Vitamin A | 1 | 2007 | 34 | 0.020 |
Why?
|
| Environmental Exposure | 1 | 1991 | 312 | 0.020 |
Why?
|
| Nutritive Value | 1 | 2007 | 31 | 0.020 |
Why?
|
| Pulmonary Circulation | 2 | 1991 | 319 | 0.020 |
Why?
|
| Magnesium | 1 | 2007 | 108 | 0.020 |
Why?
|
| Nursing | 1 | 2007 | 28 | 0.020 |
Why?
|
| Genome-Wide Association Study | 1 | 2012 | 873 | 0.020 |
Why?
|
| United Kingdom | 1 | 2007 | 176 | 0.020 |
Why?
|
| HIV Protease Inhibitors | 1 | 2007 | 45 | 0.020 |
Why?
|
| Phytotherapy | 1 | 2007 | 53 | 0.020 |
Why?
|
| Survival Rate | 1 | 2010 | 1262 | 0.020 |
Why?
|
| Mass Media | 1 | 2006 | 26 | 0.020 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2008 | 150 | 0.020 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2007 | 139 | 0.020 |
Why?
|
| Norepinephrine | 1 | 1987 | 215 | 0.020 |
Why?
|
| Consensus | 1 | 2008 | 329 | 0.020 |
Why?
|
| Aneurysm | 1 | 1986 | 16 | 0.020 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2008 | 230 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2008 | 920 | 0.020 |
Why?
|
| Fetal Diseases | 1 | 2007 | 140 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2007 | 497 | 0.020 |
Why?
|
| Hepatitis | 1 | 2006 | 31 | 0.020 |
Why?
|
| Abnormalities, Multiple | 1 | 1987 | 132 | 0.020 |
Why?
|
| Cerebral Angiography | 2 | 1982 | 56 | 0.020 |
Why?
|
| Phobic Disorders | 1 | 2005 | 20 | 0.020 |
Why?
|
| Retinal Artery | 1 | 1985 | 7 | 0.020 |
Why?
|
| Panic Disorder | 1 | 2005 | 18 | 0.020 |
Why?
|
| Clinical Protocols | 1 | 2006 | 154 | 0.020 |
Why?
|
| Workplace | 1 | 2006 | 169 | 0.020 |
Why?
|
| Cotinine | 1 | 2005 | 45 | 0.020 |
Why?
|
| Renal Artery Obstruction | 1 | 1985 | 21 | 0.020 |
Why?
|
| Anticoagulants | 1 | 2008 | 385 | 0.020 |
Why?
|
| Intestinal Obstruction | 1 | 2005 | 27 | 0.020 |
Why?
|
| Patient Acceptance of Health Care | 1 | 1989 | 423 | 0.020 |
Why?
|
| Equipment Design | 1 | 2006 | 377 | 0.020 |
Why?
|
| Multicenter Studies as Topic | 1 | 2005 | 152 | 0.020 |
Why?
|
| Sutures | 1 | 2005 | 44 | 0.020 |
Why?
|
| Food Services | 1 | 2004 | 15 | 0.020 |
Why?
|
| Child Care | 1 | 2004 | 14 | 0.020 |
Why?
|
| Physical Education and Training | 1 | 2004 | 55 | 0.020 |
Why?
|
| Aortic Valve Insufficiency | 1 | 2004 | 25 | 0.020 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2006 | 187 | 0.020 |
Why?
|
| Aspirin | 1 | 1987 | 239 | 0.020 |
Why?
|
| Vitamin D | 1 | 2007 | 252 | 0.020 |
Why?
|
| Liver Cirrhosis | 1 | 2006 | 143 | 0.020 |
Why?
|
| Mexican Americans | 1 | 2005 | 75 | 0.020 |
Why?
|
| Aortic Diseases | 1 | 1985 | 71 | 0.020 |
Why?
|
| Blood Volume | 1 | 1984 | 52 | 0.020 |
Why?
|
| Dietary Supplements | 1 | 2007 | 306 | 0.020 |
Why?
|
| Free Radical Scavengers | 1 | 2004 | 53 | 0.020 |
Why?
|
| Postoperative Care | 1 | 2005 | 167 | 0.020 |
Why?
|
| Face | 1 | 1985 | 113 | 0.020 |
Why?
|
| Preoperative Care | 1 | 2005 | 226 | 0.020 |
Why?
|
| Arteries | 1 | 2004 | 178 | 0.020 |
Why?
|
| Wakefulness | 1 | 2004 | 122 | 0.020 |
Why?
|
| Sampling Studies | 1 | 1983 | 66 | 0.020 |
Why?
|
| Biological Availability | 1 | 2003 | 106 | 0.020 |
Why?
|
| Publications | 1 | 2003 | 28 | 0.020 |
Why?
|
| Hypoxia | 1 | 2008 | 672 | 0.020 |
Why?
|
| Global Health | 1 | 2004 | 250 | 0.020 |
Why?
|
| Uncoupling Protein 2 | 1 | 2002 | 2 | 0.020 |
Why?
|
| Uncoupling Protein 3 | 1 | 2002 | 9 | 0.020 |
Why?
|
| Uncoupling Protein 1 | 1 | 2002 | 13 | 0.020 |
Why?
|
| Calorimetry, Indirect | 1 | 2002 | 64 | 0.010 |
Why?
|
| Income | 1 | 2002 | 117 | 0.010 |
Why?
|
| Lipid Metabolism | 1 | 2005 | 408 | 0.010 |
Why?
|
| Software | 1 | 2005 | 444 | 0.010 |
Why?
|
| Ion Channels | 1 | 2002 | 95 | 0.010 |
Why?
|
| Promoter Regions, Genetic | 1 | 2006 | 907 | 0.010 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2003 | 181 | 0.010 |
Why?
|
| Women's Health | 1 | 2003 | 182 | 0.010 |
Why?
|
| Creatinine | 1 | 2003 | 330 | 0.010 |
Why?
|
| Mutation | 1 | 2011 | 2524 | 0.010 |
Why?
|
| Delivery of Health Care | 1 | 2006 | 497 | 0.010 |
Why?
|
| Plant Oils | 1 | 2001 | 21 | 0.010 |
Why?
|
| Coronary Angiography | 3 | 1989 | 246 | 0.010 |
Why?
|
| Fish Oils | 1 | 2001 | 22 | 0.010 |
Why?
|
| Fish Products | 1 | 2000 | 1 | 0.010 |
Why?
|
| Hemostasis | 1 | 2001 | 40 | 0.010 |
Why?
|
| Dietary Fats, Unsaturated | 1 | 2000 | 17 | 0.010 |
Why?
|
| Edible Grain | 1 | 2000 | 34 | 0.010 |
Why?
|
| Educational Status | 1 | 2002 | 304 | 0.010 |
Why?
|
| Fatty Acids, Unsaturated | 1 | 2001 | 72 | 0.010 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2006 | 625 | 0.010 |
Why?
|
| Technetium Tc 99m Sulfur Colloid | 1 | 2000 | 5 | 0.010 |
Why?
|
| Pregnancy Complications | 1 | 2004 | 362 | 0.010 |
Why?
|
| North Carolina | 1 | 2000 | 124 | 0.010 |
Why?
|
| Eggs | 1 | 2000 | 18 | 0.010 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2005 | 425 | 0.010 |
Why?
|
| Medical Records | 1 | 2000 | 132 | 0.010 |
Why?
|
| Alcoholism | 1 | 2005 | 617 | 0.010 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2006 | 1542 | 0.010 |
Why?
|
| Radiopharmaceuticals | 1 | 2000 | 142 | 0.010 |
Why?
|
| Creatine | 1 | 1998 | 35 | 0.010 |
Why?
|
| Atrial Function | 1 | 1998 | 14 | 0.010 |
Why?
|
| Louisiana | 1 | 1998 | 19 | 0.010 |
Why?
|
| Blood Platelets | 1 | 2001 | 275 | 0.010 |
Why?
|
| Body Surface Area | 1 | 1997 | 20 | 0.010 |
Why?
|
| Genotype | 1 | 2002 | 1512 | 0.010 |
Why?
|
| Inflammation | 1 | 2006 | 1666 | 0.010 |
Why?
|
| Emetine | 1 | 1996 | 3 | 0.010 |
Why?
|
| Poisoning | 1 | 1996 | 73 | 0.010 |
Why?
|
| Fatal Outcome | 1 | 1996 | 232 | 0.010 |
Why?
|
| Steroids | 1 | 1996 | 100 | 0.010 |
Why?
|
| Mitral Valve | 1 | 1996 | 82 | 0.010 |
Why?
|
| Length of Stay | 1 | 1998 | 736 | 0.010 |
Why?
|
| HIV Infections | 1 | 2007 | 1802 | 0.010 |
Why?
|
| Videotape Recording | 1 | 1994 | 21 | 0.010 |
Why?
|
| Proteinuria | 1 | 1994 | 72 | 0.010 |
Why?
|
| Data Interpretation, Statistical | 1 | 1995 | 250 | 0.010 |
Why?
|
| Lymphatic Metastasis | 1 | 1994 | 203 | 0.010 |
Why?
|
| Wolff-Parkinson-White Syndrome | 1 | 1973 | 17 | 0.010 |
Why?
|
| Enflurane | 1 | 1993 | 1 | 0.010 |
Why?
|
| Thiopental | 1 | 1993 | 2 | 0.010 |
Why?
|
| Premedication | 1 | 1993 | 32 | 0.010 |
Why?
|
| Nitrous Oxide | 1 | 1993 | 11 | 0.010 |
Why?
|
| New York City | 1 | 1992 | 54 | 0.010 |
Why?
|
| Italy | 1 | 1992 | 61 | 0.010 |
Why?
|
| Myocarditis | 1 | 1993 | 69 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 1995 | 828 | 0.010 |
Why?
|
| Florida | 1 | 1992 | 57 | 0.010 |
Why?
|
| Sports Medicine | 1 | 1973 | 77 | 0.010 |
Why?
|
| Eosinophilia | 1 | 1993 | 138 | 0.010 |
Why?
|
| Diuretics | 1 | 1991 | 56 | 0.010 |
Why?
|
| Infant, Low Birth Weight | 1 | 1992 | 103 | 0.010 |
Why?
|
| Hospitalization | 1 | 1998 | 1215 | 0.010 |
Why?
|
| Interleukin-6 | 1 | 1994 | 537 | 0.010 |
Why?
|
| Fellowships and Scholarships | 1 | 1993 | 147 | 0.010 |
Why?
|
| Respiration | 1 | 1991 | 135 | 0.010 |
Why?
|
| Stress, Mechanical | 1 | 1992 | 331 | 0.010 |
Why?
|
| Hostility | 1 | 1989 | 8 | 0.010 |
Why?
|
| Personality Tests | 1 | 1989 | 16 | 0.010 |
Why?
|
| Triage | 1 | 1991 | 148 | 0.010 |
Why?
|
| Color | 1 | 1989 | 53 | 0.010 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 1994 | 769 | 0.010 |
Why?
|
| Kidney | 1 | 1994 | 823 | 0.010 |
Why?
|
| Peer Group | 1 | 1989 | 152 | 0.010 |
Why?
|
| Macrophages | 1 | 1994 | 955 | 0.010 |
Why?
|
| Cardiac Catheterization | 1 | 1991 | 387 | 0.010 |
Why?
|
| Cyanosis | 1 | 1987 | 16 | 0.010 |
Why?
|
| Airway Obstruction | 1 | 1987 | 117 | 0.000 |
Why?
|
| Hemiplegia | 1 | 1982 | 10 | 0.000 |
Why?
|
| Arterial Occlusive Diseases | 1 | 1982 | 61 | 0.000 |
Why?
|
| Pedigree | 1 | 1982 | 359 | 0.000 |
Why?
|
| Costs and Cost Analysis | 1 | 1979 | 153 | 0.000 |
Why?
|